Tort bar’s newest collateral damage: Preterm babies

Photo Credit: Alexander Hunter/The Washington Times

Two years ago, as we were emerging from the worst of the COVID-19 pandemic, a new health crisis — an infant formula shortage — gripped the nation. The good news was that families across the country worked with friends, churches, synagogues, mosques, community groups and milk banks to ensure their babies got the nutrition they needed.

Now, new litigation involving preterm infant formula and human milk fortifiers threatens to upend access to these critical products. Once again, tort lawyers, sensing a big payday, have put greed before civic duty by putting at risk one of our most at-risk populations — premature infants.

Lawsuits alleging a link between necrotizing enterocolitis, or NEC, preterm infant formula and human milk fortifiers have popped up across the country. In March, an Illinois jury awarded $60 million to a woman whose premature infant died from NEC, an intestinal disease afflicting premature and low-birth-weight babies, finding that Mead Johnson (the manufacturer of Enfamil formula) failed to warn her about the potential risk of NEC.

These “failure to warn” claims are odd and out of place because parents don’t buy preterm infant formula or human milk fortifiers at the grocery store. These are highly specialized products that neonatal doctors in hospitals direct for specific use for infants. Preterm baby formula and milk fortifiers carry mandatory labeling language that is strictly regulated by the Food and Drug Administration.


 
Sign Up for Our Email Newsletter

RECENT NEWS

New JCI Viewpoint: FDA Must Rethink How It Evaluates Precision Medicines for Rare Diseases

New JCI Viewpoint: FDA Must Rethink How It Evaluates Precision Medicines for Rare Diseases

Authors argue that rare disease innovation requires learning more from fewer patients—not enrolling more patients...  Read more

Qualifying Single-Source Drug Policy, Medicare Price Negotiation, and the Incentives for Meaningful Post-Approval Innovation

Qualifying Single-Source Drug Policy, Medicare Price Negotiation, and the Incentives for Meaningful Post-Approval Innovation

CMS should demand evidence from manufacturers and be prepared to defend its own assumptions about innovation. Its next st...  Read more

Troubling Trends: Systemic Practices in Texas' Non-Profit Hospitals That Inflate Health Care Costs

Troubling Trends: Systemic Practices in Texas' Non-Profit Hospitals That Inflate Health Care Costs

Texas has an opportunity to lead rather than react. Better measurement would strengthen public confidence without diminis...  Read more

DRUGWONKS BLOG